生活方式与二甲双胍干预对超重或肥胖糖调节受损人群进展为糖尿病及逆转为血糖正常风险的影响
基于糖尿病预防计划(DPP)基线19项临床变量和Cox比例风险模型,评估依从生活方式、二甲双胍或安慰剂干预者3年内进展为糖尿病和逆转为血糖正常(NGR)的风险。依从生活方式干预且基线进展风险最低者3年进展为糖尿病的绝对风险降低8%,逆转为NGR的绝对可能性增加35%;依从二甲双胍且基线进展风险最低者进展风险无降低,逆转为NGR的绝对可能性增加17%。基线进展风险最高者依从生活方式干预的绝对风险降低39%、逆转为NGR的绝对可能性增加24%,依从二甲双胍干预的绝对风险降低25%、逆转为NGR的绝对可能性增加11%。
要点
- 基线19项临床变量中11项可预测进展为糖尿病,6项可预测逆转为血糖正常。
- 基线进展风险最低者依从生活方式干预3年糖尿病绝对风险降低8%,逆转NGR绝对可能性增加35%。
- 基线进展风险最高者依从生活方式干预糖尿病绝对风险降低39%,依从二甲双胍降低25%。
核心结论
- 基于个体风险的模型可用于超重或肥胖的空腹高血糖和糖耐量受损成人,帮助其权衡生活方式和二甲双胍干预的获益与可行性以促进个体化决策。
研究设计与样本
- 利用糖尿病预防计划(DPP)基线评估时测量的19项临床变量值和Cox比例风险模型,分别评估依从生活方式、二甲双胍和安慰剂干预的DPP参与者3年内进展为糖尿病和逆转为血糖正常的风险。
- 依从定义为:生活方式组参与者在6个月时体重较初始体重减轻≥5%;二甲双胍组和安慰剂组参与者在6个月随访时报告服用处方药物的比例≥80%。
主要发现
- 基线19项临床变量中11项预测进展为糖尿病,6项预测逆转为血糖正常。
- 与进展为糖尿病风险最低且依从安慰剂的参与者相比,进展风险最低且依从生活方式干预者3年进展为糖尿病的绝对风险降低8%,逆转为血糖正常的绝对可能性增加35%。
- 与进展为糖尿病风险最低且依从安慰剂的参与者相比,进展风险最低且依从二甲双胍干预者3年进展为糖尿病的风险无降低,逆转为血糖正常的绝对可能性增加17%。
- 进展为糖尿病风险最高且依从生活方式干预者3年进展为糖尿病的绝对风险降低39%,逆转为血糖正常的绝对可能性增加24%。
- 进展为糖尿病风险最高且依从二甲双胍干预者3年进展为糖尿病的绝对风险降低25%,逆转为血糖正常的绝对可能性增加11%。
临床怎么用
- 作者认为,这些模型可被超重或肥胖的空腹高血糖和糖耐量受损成人用于促进个体化决策,使其能够明确权衡生活方式和二甲双胍干预的获益与可行性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Both lifestyle and metformin interventions can delay or prevent progression to type 2 diabetes mellitus (DM) in people with impaired glucose regulation, but there is considerable interindividual variation in the likelihood of receiving benefit. Understanding an individual's 3-year risk of progressing to DM and regressing to normal glucose regulation (NGR) might facilitate benefit-based tailored treatment. RESEARCH DESIGN AND METHODS: We used the values of 19 clinical variables measured at the Diabetes Prevention Program (DPP) baseline evaluation and Cox proportional hazards models to assess the 3-year risk of progression to DM and regression to NGR separately for DPP lifestyle, metformin, and placebo participants who were adherent to the interventions. Lifestyle participants who lost ≥5% of their initial body weight at 6 months and metformin and placebo participants who reported taking ≥80% of their prescribed medication at the 6-month follow-up were defined as adherent. RESULTS: Eleven of 19 clinical variables measured at baseline predicted progression to DM, and 6 of 19 predicted regression to NGR. Compared with adherent placebo participants at lowest risk of developing diabetes, participants at lowest risk of developing diabetes who adhered to a lifestyle intervention had an 8% absolute risk reduction (ARR) of developing diabetes and a 35% greater absolute likelihood of reverting to NGR. Participants at lowest risk of developing diabetes who adhered to a metformin intervention had no reduction in their risk of developing diabetes and a 17% greater absolute likelihood of reverting to NGR. Participants at highest risk of developing DM who adhered to a lifestyle intervention had a 39% ARR of developing diabetes and a 24% greater absolute likelihood of reverting to NGR, whereas those who adhered to the metformin intervention had a 25% ARR of developing diabetes and an 11% greater absolute likelihood of reverting to NGR. CONCLUSIONS: Unlike our previous analyses that sought to explain population risk, these analyses evaluate individual risk. The models can be used by overweight and obese adults with fasting hyperglycemia and impaired glucose tolerance to facilitate personalized decision-making by allowing them to explicitly weigh the benefits and feasibility of the lifestyle and metformin interventions.
引用
- Herman WH, Pan Q, Edelstein SL, et al. Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. Diabetes Care. 2017. PMID: 29021207. doi:10.2337/dc17-1116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。